IgG Antibodies Are the Primary Antibody Class in ITP Pathogenesis
IgG antibodies are the predominant immunoglobulin class involved in immune thrombocytopenic purpura (ITP), mediating platelet destruction through opsonization and subsequent clearance by the reticuloendothelial system. The international consensus guidelines explicitly reference platelet-associated IgG (PaIgG) as the key antibody marker, though they note it is elevated in both immune and non-immune thrombocytopenia 1.
Pathophysiologic Mechanism
The disease mechanism centers on IgG autoantibodies directed against platelet surface glycoproteins (particularly GPIIb/IIIa and GPIb/IX complexes). These antibodies coat platelets, marking them for premature destruction primarily in the spleen and liver 1. The guidelines emphasize that ITP pathophysiology has evolved beyond simple antibody-mediated destruction to include impaired platelet production and T cell-mediated effects, but IgG remains the central mediator 1.
Role of Other Antibody Classes
While IgG is dominant, IgM antibodies can also contribute to platelet destruction in some patients. Research demonstrates that 57% of ITP patients have increased platelet-associated IgM, which correlates significantly with complement (C3) deposition on platelets 2. IgM antibodies can activate complement and enhance platelet clearance, potentially working synergistically with IgG antibodies 2.
Clinical Testing Implications
The guidelines explicitly recommend against routine antiplatelet antibody testing because:
- Glycoprotein-specific antibody assays lack sufficient sensitivity and specificity
- PaIgG elevation occurs in both immune and non-immune thrombocytopenia
- These tests do not guide patient management or treatment decisions 1
The diagnosis of ITP remains primarily clinical, based on isolated thrombocytopenia (platelet count <100 × 10⁹/L) after excluding other causes through history, physical examination, complete blood count, and peripheral blood smear evaluation 1.
Important Distinction from TTP
Note that this question concerns immune thrombocytopenic purpura (ITP), not thrombotic thrombocytopenic purpura (TTP). TTP has a completely different mechanism involving ADAMTS13 deficiency caused by either autoantibodies (immune TTP) or genetic mutations (congenital TTP) 3, 4. The similar naming can cause confusion, but these are distinct disease entities.